MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$15,160K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from underwritten regis...
Maturities of marketable securit...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepaid expenses and other curre...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-44,727
-24,208
-34,568
-30,087
Depreciation expense
391
444
499
571
Stock-based compensation expense
9,187
7,109
6,073
3,864
Non-cash lease expense
843
831
804
787
Amortization of premiums on marketable securities, net
-7
2
227
278
Amortization of debt discount and debt issuance costs
127
371
-
-
Other items, net
0
18
0
0
Accounts receivable
-
20,000
-
-
Prepaid expenses and other current assets
1,940
-404
433
758
Other assets
-193
605
-163
-356
Accounts payable
-1,794
2,212
-1,125
-748
Accrued expenses and other liabilities
3,976
-4,066
1,963
1,519
Operating lease liabilities
-928
-915
-879
-825
Long-term liabilities
-388
-706
-
-
Net cash used in operating activities
-15,053
-39,113
-27,730
-24,642
Purchases of marketable securities
162,399
23,632
120,853
66,815
Maturities of marketable securities
34,000
30,000
17,500
-
Purchases of property and equipment
107
93
34
68
Net cash used in investing activities
-128,506
6,275
-103,387
-66,883
Proceeds from underwritten registered offering, net
145,659
-
-
-
Payment of offering costs-Underwriting Agreement
864
226
-
-
Proceeds from initial public offering, net of offering costs paid
-
-
0
0
Proceeds from debt issuance, net
0
39,401
-
-
Proceeds from private placement, net of offering costs paid
-
-
-481
141,748
Payment of debt issuance costs
53
886
-
-
Proceeds from exercise of stock option awards
1,696
4,079
3,426
2,009
Proceeds from issuance of common stock under the 2025 employee stock purchase plan
998
-
644
0
Payment of success fee derivative
-
-
0
0
Proceeds from exercise of pre-funded warrants
-
-
1
-
Payment of offering costs-Private Placement
0
11
-
-
Net cash provided by financing activities
147,436
42,357
3,590
143,757
Net increase in cash, cash equivalents and restricted cash
3,877
9,519
-127,527
52,232
Cash, cash equivalents, and restricted cash at beginning of the period
199,854
190,335
317,862
197,900
Cash, cash equivalents, and restricted cash at end of the period
203,731
-
-
-
Cash and cash equivalents
202,643
-
-
-
Restricted cash
1,088
-
-
-
Total cash, cash equivalents, and restricted cash
203,731
199,854
190,335
317,862
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
underwritten registered...
$145,659K
Proceeds from exercise of
stock option awards
$1,696K
(1246.03%↑ Y/Y)
Proceeds from issuance of
common stock under the...
$998K
(63.07%↑ Y/Y)
Net cash provided by
financing activities
$147,436K
(15.19%↑ Y/Y)
Canceled cashflow
$917K
Net increase in
cash, cash...
$3,877K
(-94.28%↓ Y/Y)
Canceled cashflow
$143,559K
Payment of offering
costs-Underwriting Agreement
$864K
Payment of debt issuance
costs
$53K
Maturities of marketable
securities
$34,000K
something is missing
$20,000K
Stock-based compensation
expense
$9,187K
(42.15%↑ Y/Y)
Accrued expenses and
other liabilities
$3,976K
(515.46%↑ Y/Y)
Non-cash lease expense
$843K
(-45.37%↓ Y/Y)
Depreciation expense
$391K
(-70.67%↓ Y/Y)
Other assets
-$193K
(-972.22%↓ Y/Y)
Amortization of debt discount
and debt issuance...
$127K
Amortization of premiums on
marketable securities, net
-$7K
Net cash used in
investing activities
-$128,506K
(-18470.23%↓ Y/Y)
Net cash used in
operating activities
-$15,053K
(74.73%↑ Y/Y)
Canceled cashflow
$34,000K
Canceled cashflow
$34,724K
Purchases of marketable
securities
$162,399K
Net loss
-$44,727K
(32.71%↑ Y/Y)
Purchases of property and
equipment
$107K
(-84.54%↓ Y/Y)
Prepaid expenses and
other current assets
$1,940K
(10.86%↑ Y/Y)
Accounts payable
-$1,794K
(-197.18%↓ Y/Y)
Operating lease
liabilities
-$928K
(42.72%↑ Y/Y)
Long-term liabilities
-$388K
Buy us a coffee
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)